Apricus Biosciences, Inc.
23.05.2011 19:38
---------------------------------------------------------------------------
SAN DIEGO, 2011-05-23 19:37 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) today announced that Linda Smibert, Vice President,
Business Development at the Company's NexMed, USA, Inc. subsidiary, will
present at the Euro-Biotech Partnering Forum 2011 conference in Paris, France,
on Tuesday, May 24th at 10:00 am CET.
Ms. Smibert's presentation will include an update of the Company's portfolio,
and current worldwide licensing and commercialization efforts for Vitaros(r) for
erectile dysfunction ('ED'), in our continual efforts to finalize a partnership
for Canada and Europe, this year. In addition, Ms. Smibert will be giving
one-to-one presentations on the Company's four later clinical-stage products,
Femprox(r) for female sexual arousal disorder, MycoVa? for onychomycosis,
PrevOnco? for liver cancer, and RayVa? for Raynaud's phenomenon, in patients
with systemic sclerosis. Mark Wilson, Vice President, NexACT(r) Technology
Licensing, will join Ms. Smibert to focus on partnering the use of NexACT(r)
Technology to pharmaceutical and biotechnology companies.
The Company has received approval for its Vitaros(r) product for ED in Canada,
filed for approval for this product in the European Union through the
Decentralized Procedure and received guidance from the Swiss regulatory
authorities to file for approval in that country -- an approval that may permit
the Company to receive additional approvals in other non-EU European countries.
Apricus Bio is also planning to make initial filings for the product for ED in
the MENA (Middle Eastern and North African) countries in 2011. In addition,
Apricus Bio is in negotiations with various partners to license and
commercialize Vitaros(r) for ED in Canada and certain European countries, in
order to complement the partnerships for this product that the Company has
already announced in the last six months. These include partnerships in Italy
with Bracco SpA, in the Gulf Countries and certain countries in the Middle East
with Elis Pharmaceuticals, and in Israel and the Palestinian Territories with
the Neopharm Group.
'The Euro-Biotech Partnering Forum is an important meeting for Apricus Bio
since it provides a centralized forum for us to continue partnership
negotiations in a very condensed and focused mode,' stated Dr. Bassam Damaj,
President and Chief Executive Officer of Apricus Bio.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has
leveraged the flexibility of its clinically-validated NexACT(r) drug delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the
development and commercialization of such compounds to pharmaceutical and
biotechnology companies worldwide. In addition, the Company is seeking to
monetize its existing product pipeline, including its first product, Vitaros(r),
approved in Canada for the treatment of erectile dysfunction, which is
currently expected to be available on the Canadian market in 2011, as well as
compounds in development from pre-clinical through Phase III, currently focused
on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain,
Anti-Infectives, Diabetes and Cosmeceuticals among others.
For further information on Apricus Bio, visit http://www.apricusbio.com and for
information on its subsidiaries please visit www.nexmedusa.com or
www.bio-quant.com. You can also receive information at
http://twitter.com/apricusbio and http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further development products and
product candidates, to have its products such as Vitaros(r), Femprox(r),
MycoVa?,
PrevOnco?, and RayVa? among others and product candidates approved by relevant
regulatory authorities, to successfully commercialize such products and product
candidates and to achieve its other development, commercialization and
financial goals. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the risk
factors set forth in the Company's most recent annual report on Form 10-K,
subsequent quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are available from the SEC's website or without
charge from the Company.
CONTACT: Apricus Biosciences, Inc.
Edward Cox, V.P.
Corporate Development & Investor Relations
Apricus Biosciences, Inc.
(858) 848-4249
ecox@apricusbio.com
Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX
23.05.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Apricus Biosciences to Present at the Euro-Biotech Partnering Forum 2011 to Further Its Partnership Efforts
| Source: EQS Group AG